Race Oncology Limited (RAONF)
USD 1.22
(0.0%)
USD 1.22
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 1.91 Million AUD | 66.39% |
| 2023 | 767.09 Thousand AUD | -21.56% |
| 2022 | 977.99 Thousand AUD | 149.03% |
| 2021 | 392.72 Thousand AUD | 134.11% |
| 2020 | 167.75 Thousand AUD | 24.43% |
| 2019 | 134.81 Thousand AUD | -41.08% |
| 2018 | 228.82 Thousand AUD | -17.95% |
| 2017 | 278.87 Thousand AUD | -4.36% |
| 2016 | 291.6 Thousand AUD | 145.5% |
| 2015 | 118.78 Thousand AUD | -10.05% |
| 2014 | 132.04 Thousand AUD | 1014.31% |
| 2013 | 11.85 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 638.75 Thousand USD | 0.0% |
| 2024 Q4 | 1.91 Million AUD | 0.0% |
| 2024 Q1 | 638.75 Thousand AUD | -16.73% |
| 2023 Q2 | 836.37 Thousand USD | 0.0% |
| 2023 Q4 | 767.09 Thousand AUD | -33.4% |
| 2023 Q3 | 1.15 Million AUD | 37.71% |
| 2023 Q1 | 836.37 Thousand AUD | -14.48% |
| 2023 FY | 767.09 Thousand AUD | -21.56% |
| 2022 Q1 | 785.64 Thousand AUD | 100.05% |
| 2022 FY | 977.99 Thousand AUD | 149.03% |
| 2022 Q4 | 977.99 Thousand AUD | -31.0% |
| 2022 Q3 | 1.41 Million AUD | 80.4% |
| 2022 Q2 | 785.64 Thousand USD | 0.0% |
| 2021 Q4 | 392.72 Thousand AUD | -24.92% |
| 2021 Q3 | 523.1 Thousand AUD | 357.46% |
| 2021 Q1 | 114.35 Thousand AUD | -31.83% |
| 2021 Q2 | 114.35 Thousand USD | 0.0% |
| 2021 FY | 392.72 Thousand AUD | 134.11% |
| 2020 Q2 | 221.33 Thousand USD | 0.0% |
| 2020 Q3 | 243.65 Thousand AUD | 10.08% |
| 2020 Q4 | 167.75 Thousand AUD | -31.15% |
| 2020 FY | 167.75 Thousand AUD | 24.43% |
| 2020 Q1 | 221.33 Thousand AUD | 64.17% |
| 2019 Q3 | 192.11 Thousand AUD | -34.33% |
| 2019 Q1 | 292.55 Thousand AUD | -5.54% |
| 2019 FY | 134.81 Thousand AUD | -41.08% |
| 2019 Q4 | 134.81 Thousand AUD | -29.83% |
| 2019 Q2 | 292.55 Thousand AUD | 0.0% |
| 2018 Q1 | 166.59 Thousand AUD | -54.18% |
| 2018 FY | 228.82 Thousand AUD | -17.95% |
| 2018 Q4 | 309.7 Thousand AUD | 0.0% |
| 2018 Q3 | 309.7 Thousand AUD | 85.91% |
| 2018 Q2 | 166.59 Thousand AUD | 0.0% |
| 2017 Q3 | 363.57 Thousand AUD | 48.43% |
| 2017 FY | 278.87 Thousand AUD | -4.36% |
| 2017 Q4 | 363.57 Thousand AUD | 0.0% |
| 2017 Q2 | 244.94 Thousand AUD | 0.0% |
| 2017 Q1 | 244.94 Thousand AUD | -37.45% |
| 2016 Q2 | 236.03 Thousand AUD | 0.0% |
| 2016 Q1 | 236.03 Thousand AUD | 98.71% |
| 2016 Q4 | 391.62 Thousand AUD | 0.0% |
| 2016 Q3 | 391.62 Thousand AUD | 65.92% |
| 2016 FY | 291.6 Thousand AUD | 145.5% |
| 2015 Q1 | - AUD | 0.0% |
| 2015 Q4 | 118.78 Thousand AUD | 0.0% |
| 2015 Q3 | 118.78 Thousand AUD | 0.0% |
| 2015 FY | 118.78 Thousand AUD | -10.05% |
| 2014 FY | 132.04 Thousand AUD | 1014.31% |
| 2013 FY | 11.85 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 96.405% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 80.0% |
| SQZ Biotechnologies Company | 50.03 Million USD | 96.17% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 97.356% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 96.753% |
| Mesoblast Limited | 188.44 Million USD | 98.983% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 50.241% |
| Genus plc | 485 Million USD | 99.605% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 67.199% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 23.84% |
| Marizyme, Inc. | 26.67 Million USD | 92.816% |
| ContraFect Corporation | 32.53 Million USD | 94.109% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 49.568% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 3.275% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 49.932% |
| Intellipharmaceutics International Inc. | 12 Million USD | 84.041% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 83.729% |
| MultiCell Technologies, Inc. | 1617.67 USD | -118368.229% |
| Accustem Sciences Inc. | 1.07 Million USD | -77.572% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 97.525% |
| EV Biologics, Inc. | 2.11 Million USD | 9.392% |
| Q BioMed Inc. | 8.13 Million USD | 76.436% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 97.689% |
| Neon Bloom, Inc. | 1.22 Million USD | -56.288% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 62.759% |
| Biomind Labs Inc. | 1.49 Million USD | -27.88% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 99.215% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 89.587% |
| Skye Bioscience, Inc. | 14.07 Million USD | 86.382% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 4.662% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -1248.693% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 79.754% |
| IMV Inc. | 37.93 Million USD | 94.948% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -852.895% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 66.647% |
| GB Sciences, Inc. | 5.41 Million USD | 64.626% |
| Alpha Cognition Inc. | 7.16 Million USD | 73.252% |
| HST Global, Inc. | 593.59 Thousand USD | -222.852% |
| CSL Limited | 18.62 Billion USD | 99.99% |
| Halberd Corporation | 728.71 Thousand USD | -162.985% |
| Enzolytics Inc. | 365.26 Million USD | 99.475% |
| Resverlogix Corp. | 67.39 Million USD | 97.156% |
| Affymax, Inc. | 8.87 Million USD | 78.397% |
| SYBLEU INC | 681.41 Thousand USD | -181.243% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -128.491% |
| argenx SE | 444.95 Million USD | 99.569% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 97.442% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -11.81% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 83.9% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 47.712% |
| AVAX Technologies, Inc. | 3.99 Million USD | 52.014% |
| Zenith Capital Corp. | 27.56 Thousand USD | -6851.377% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.855% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -703.014% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 48.681% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -181.482% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 98.386% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 78.806% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -2763.37% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -33.655% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 96.187% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 29.326% |
| BioStem Technologies, Inc. | 15.9 Million USD | 87.951% |
| ONE Bio Corp. | 27.49 Million USD | 93.03% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -312.401% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -6885.838% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -52.195% |
| Agentix Corp. | 2.51 Million USD | 23.665% |
| LadRx Corporation | 2.2 Million USD | 12.911% |
| Cell Source, Inc. | 15.8 Million USD | 87.876% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -4187.688% |
| Regen BioPharma, Inc. | 5.45 Million USD | 64.885% |
| Regen BioPharma, Inc. | 5.45 Million USD | 64.885% |
| NovAccess Global Inc. | 7.86 Million USD | 75.62% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 92.256% |
| Itoco Inc. | 1.65 Million USD | -15.926% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 6.587% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 68.318% |
| Kadimastem Ltd | 3.5 Million USD | 45.321% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -354.595% |
| CytoDyn Inc. | 127.89 Million USD | 98.502% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -4484.858% |
| Mobile Lads Corp. | 1.31 Million USD | -45.903% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -22.348% |
| Qrons Inc. | 1.48 Million USD | -28.73% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 82.649% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -136.948% |
| Rebus Holdings, Inc. | 5.24 Million USD | 63.441% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 68.593% |
| International Stem Cell Corporation | 5.27 Million USD | 63.683% |
| Bioxytran, Inc. | 3.24 Million USD | 41.024% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -206.232% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 58.493% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 95.325% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 91.393% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 5.38% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 65.016% |
| Neutra Corp. | 973.52 Thousand USD | -96.853% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 93.395% |
| PureTech Health plc | 125.58 Million USD | 98.474% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 48.992% |
| IXICO plc | 1.9 Million USD | -0.849% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 90.665% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.145% |
| CSL Limited | 18.62 Billion USD | 99.99% |
| Cellectis S.A. | 249.36 Million USD | 99.231% |